---

High-Intensity Focused Ultrasound (HIFU) — Complete Overview

---

1. Definition

"HIFU is a unique thermal ablation technology in that it can be administered in an entirely noninvasive, extracorporeal fashion minimizing or eliminating the risk for tumor seeding, hemorrhage, or urinary extravasation." — Campbell Walsh Wein Urology

---

2. Historical Background

• The concept dates to Wood et al. in the 1920s, where HIFU was first proposed as an ablative technique.
• Research stagnated for decades due to lack of adequate imaging technologies.
• With the development of ultrasonography, CT, and MRI, accurate localization and real-time monitoring became possible, reviving clinical interest.
• Over the past 20 years, commercially available, precise HIFU delivery devices have been developed, particularly for urology.

— Hinman's Atlas of Urologic Surgery

---

3. Physical Principles

Ultrasound Fundamentals

• Ultrasound is an inaudible, high-frequency pressure wave emitted by a transducer.
• Diagnostic ultrasound uses 1–20 MHz frequencies.
• HIFU uses 0.8–4 MHz frequencies, but at energy levels approximately 10,000× greater than diagnostic ultrasound.

Focusing Principle

• When ultrasound waves are focused with an appropriately shaped transducer, energy is concentrated at a focal point.
• The intensity at the focal point can exceed 3,500 W/cm³, while surrounding tissue absorbs minimal energy.
• This achieves cell death at the focus while adjacent tissue is spared.

— Campbell Walsh Wein Urology

---

4. Mechanisms of Tissue Destruction

A. Thermal (Heating) Mechanism

• Ultrasound waves are absorbed by tissue, causing molecular agitation.
• Resulting friction generates heat, rapidly raising tissue temperature to 80–100°C within seconds.
• This causes:
  • Protein denaturation (melting of the lipid bilayer of the cellular membrane)
  • Denaturation of lipoprotein structures in organelle membranes
  • Coagulative necrosis — the predominant histologic finding
• Temperature elevation of 50–95°C in 1–2 seconds is sufficient for irreversible cell death.
• Heating is favored at higher ultrasound frequencies.

B. Cavitation (Mechanical) Mechanism

• At intensities >3,500 W/cm³, microbubbles form within the tissue (cavitation).
• These bubbles undergo rapid collapse, generating extremely high local temperatures and a mechanically disrupting "shock wave" effect — similar to extracorporeal shock wave lithotripsy (ESWL).
• Cavitation is favored at lower ultrasound frequencies.
• This adds further mechanical destruction on top of thermal injury.

— Hinman's Atlas of Urologic Surgery; Campbell Walsh Wein Urology; Dermatology 2-Volume Set

---

5. Instrumentation

Core Component: The Transducer

• The piezoelectric transducer generates ultrasound waves.
• It is specially curved/shaped so that waves converge at a defined focal point — delivering maximum energy at the target depth.
• The same transducer may serve dual purpose: treatment delivery + real-time imaging.

Key Design Parameters

Monitoring Systems

1. Diagnostic Ultrasound (most common):
   • Mounted with the treatment probe for real-time imaging
   • Monitors gray-scale hyperechoic changes (hyperechoic = microbubble/steam formation from heated tissue)
   • Portable and cost-effective; however, bubbles cause imaging artifacts
2. MRI Guidance (MR-HIFU / MRgFUS):
   • Uses MR thermometry for real-time temperature mapping in the target and surrounding structures (urethra, sphincter)
   • Higher cost and less accessible but more precise for deep targets

Rectal Cooling System

• Devices used for prostate treatment include a cool water circulating system within the endorectal probe to prevent rectal wall thermal injury.
• Real-time rectal wall temperature monitoring and patient movement detection are built-in safety features.

---

6. Commercial HIFU Devices

1. Sonablate (SonaCare Inc., USA)

• Mobile, minimally invasive endorectal probe device
• Treats prostates up to 40 mL
• Lesion size: 10–12 mm diameter
• Features real-time imaging, mpMRI fusion capability
• Color-coded temperature monitoring of treatment zone and adjacent structures (neurovascular bundles, rectal wall)
• Robotic transducer for whole-gland targeting
• Patient position: extended lithotomy

2. Ablatherm (EDAP TMS, France)

• Semi-automated device with endorectal probe
• Consists of: treatment module + control module + endorectal probe (with both treatment and imaging transducers)
• Lesion size: 19–26 mm via predefined power protocols
• Real-time intraoperative imaging with adjustable energy delivery
• Rectal cooling + movement detection safety systems
• Patient position: right lateral decubitus

— Hinman's Atlas of Urologic Surgery

3. MRgFUS / TULSA Systems

• MRI-guided focused ultrasound (MRgFUS): In-bore MRI guidance with thermometry
• Transurethral Ultrasound Ablation (TULSA): Miniaturized probe inserted transurethrally — especially useful for anterior prostate lesions that are harder to reach transrectally
• Spatial control of ablation within 1.3 mm on MRI thermometry

— Campbell Walsh Wein Urology

---

7. Working / Procedure

Pre-procedure

• Bowel preparation (full bowel prep the night before, or enema 1 hour prior)
• Antimicrobial prophylaxis: IV broad-spectrum antibiotics (metronidazole, cefuroxime, gentamicin)
• mpMRI for lesion characterization and treatment planning
• Patient consent with discussion of risks
• Anticoagulant/antiplatelet management

Anesthesia

• General or spinal anesthesia required
• If spinal: heavy sedation to prevent movement
• Paralysis + ventilation if prostate movement from breathing is detected
• ⚠️ Nitrous oxide is CONTRAINDICATED — causes microbubble formation in the prostate, producing artifactual changes that impair safe energy delivery

— Hinman's Atlas of Urologic Surgery

Intraoperative Steps

1. Patient positioned (lithotomy or lateral decubitus)
2. Urethral catheter inserted for planning
3. Optional pre-procedure mini-TURP (4–6 weeks prior) to reduce prostate height and stricture risk
4. Digital rectal exam to confirm empty rectum
5. Endorectal HIFU probe introduced with lubricating jelly
6. Prostate mapped ultrasonographically; target treatment area defined
7. If mpMRI fusion used — calibrated at this step
8. Rectal cooling system activated
9. Energy delivered under real-time monitoring
10. Operator monitors for hyperechoic changes (steam/microbubbles = effective treatment)
11. Treatment paused if rectal wall or other structures are at risk

Post-procedure

• Usually day-case procedure (discharged same day)
• Urethral catheter left in place 5–10 days
• Oral antibiotics for 7 days (fluoroquinolones or beta-lactams)
• Alpha-blockers for up to 14 days
• Mild pain — simple oral analgesics usually sufficient
• PSA monitoring (may take months to reach nadir)
• Follow-up: 3-monthly × 1 year → 6-monthly × 1 year → annually
• mpMRI at 12 months; biopsy if recurrence suspected

— Hinman's Atlas of Urologic Surgery

---

8. Ablation Zone and Treatment Planning

Ablation Strategies (Prostate):

— Hinman's Atlas of Urologic Surgery

---

9. Clinical Applications

— Multiple sources: Dermatology 2-Volume Set; Grainger & Allison's Radiology; Current Surgical Therapy 14e; Sabiston Textbook of Surgery

---

10. Indications (Prostate Cancer — Most Established)

• Clinically localized prostate cancer
• Gleason score ≥ 3+4 (clinically significant disease)
• Tumor volume > 0.2 mL, visible on mpMRI and concordant with histology
• Patients with serious comorbidities precluding surgery or radiation
• Prior therapies excluding major surgery or RT
• Can be considered for salvage after radiotherapy failure

— Hinman's Atlas of Urologic Surgery; Miller's Anesthesia

---

11. Contraindications / Limitations

• Prostate size > 40 mL (Sonablate limit) — may require pre-TURP downsizing
• Anterior lesions — more difficult to treat with transrectal HIFU (energy dissipation over intervening tissue; edema displaces targets)
• Calcifications in the treatment zone interfere with energy delivery
• Inadequate imaging window (bowel gas, obesity)
• Nitrous oxide anesthesia (absolute contraindication intraoperatively)
• Respiratory movement — limits extracorporeal HIFU for kidney (acoustic shadowing, refraction)

---

12. Advantages

---

13. Complications

— Current Surgical Therapy 14e; Hinman's Atlas; Dermatology 2-Volume Set

---

14. Monitoring Modalities Summary

---

15. Emerging Developments

• TULSA (Transurethral Ultrasound Ablation): Miniaturized intraluminal probe enabling precise anterior prostate treatment under in-bore MRI guidance — spatial control within 1.3 mm
• Transcranial MRgFUS: Focused ultrasound through the skull for neurologic disorders (essential tremor, Parkinson's)
• MRI-guided breast HIFU: Complete ablation achieved in ~46% of patients in systematic review; ongoing refinement
• Extracorporeal renal HIFU: Currently investigational; hampered by respiratory motion and incomplete ablation rates

---

Summary Table

---

---

High-Intensity Focused Ultrasound (HIFU) — Complete Reference

---

1. Definition

"HIFU is a unique thermal ablation technology in that it can be administered in an entirely noninvasive, extracorporeal fashion, minimizing or eliminating the risk for tumor seeding, hemorrhage, or urinary extravasation." — Campbell Walsh Wein Urology

---

2. Historical Background

"In the early 1990s a number of authors investigated the therapeutic uses of high-intensity focused ultrasound (HIFU). Madersbacher et al. were the first to report the safety and efficacy of HIFU in patients with symptomatic BPH." — Campbell Walsh Wein Urology

---

3. Physical Principles

Ultrasound as a Wave

Frequency Comparison

The Focusing Principle

"The energy levels delivered are about 10,000 times greater in a HIFU beam than a modern diagnostic ultrasound beam. This amount of energy can rapidly increase the temperature in the beam's focus to 80°C or higher, which is adequate for causing cell death. Outside of the focus, little damage occurs to tissue." — Hinman's Atlas of Urologic Surgery

---

4. Mechanisms of Tissue Destruction

---

Mechanism 1 — Thermal Coagulation (Primary)

1. Ultrasound waves travel through tissue and are absorbed by molecules
2. Absorption causes molecular agitation — the molecules vibrate at ultrasonic frequencies
3. The resulting intermolecular friction generates heat
4. Tissue temperature rises to 55–100°C within 1–2 seconds
5. This causes:
   • Melting of the phospholipid bilayer of the cell membrane
   • Denaturation of proteins (structural and enzymatic)
   • Denaturation of lipoprotein structures in organelle membranes (mitochondria, ER, nucleus)
   • Irreversible coagulative necrosis

"The ultrasound waves are absorbed by the tissue and agitate the molecules within. The subsequent friction generates heat and the temperature in the tissue affected can rise to 100°C in seconds. The heat denatures protein and lipoprotein structures in the cell membrane and the membranes of organelles contained within." — Hinman's Atlas of Urologic Surgery

"The focused ultrasound waves cause rapid (1–2 seconds) temperature elevation within the targeted tissue up to 50°C to 95°C. This causes melting of the lipid bilayer of the cellular membrane and protein denaturation, leading to tissue necrosis, whereas tissues outside the targeted area are spared." — Current Surgical Therapy 14e

---

Mechanism 2 — Acoustic Cavitation (Secondary)

1. At very high intensities (> 3,500 W/cm³), dissolved gases in tissue nucleate and form microbubbles
2. These bubbles undergo rapid oscillation (stable cavitation) and then violent collapse (inertial/transient cavitation)
3. Bubble collapse generates:
   • Extremely high local temperatures (thousands of degrees at the bubble wall)
   • High-pressure shock waves — mechanically destructive, analogous to ESWL (extracorporeal shock wave lithotripsy)
   • Free radical production — chemical damage to DNA and membranes
4. This causes additional mechanical tissue disruption on top of thermal injury

"At sufficiently high intensities (>3500 W/cm³), cavitation and microbubble formation occur that yield extremely high temperatures and a mechanically disrupting 'shock wave' effect similar to that seen with extracorporeal shock wave lithotripsy." — Campbell Walsh Wein Urology

• Thermal heating is favored at higher frequencies
• Cavitation is favored at lower frequencies

---

Three Mechanisms Summary (Dermatology perspective)

"Intensity is concentrated near the focal point, to the extent that tissue damage can occur by one or more of three mechanisms — heating, cavitation, or shock waves. Heating is favored at high ultrasound frequencies while cavitation (a rapidly expanding gas bubble) is favored at low ultrasound frequencies; shock waves are high-pressure, supersonic pressure waves that can be very destructive." — Dermatology 2-Volume Set 5e

---

5. Histologic Result

• Cell outlines preserved but nuclear pyknosis/karyolysis
• Ghost cells with no viable nuclei
• Sharp demarcation between treated and untreated tissue
• Surrounding tissue intact (the hallmark of precise HIFU ablation)

---

6. Instrumentation

A. The Transducer — Core Component

• Is made of piezoelectric crystal material (converts electrical energy → acoustic energy)
• Is curved/concave in shape so that emitted waves converge at a preset focal depth
• Operates at 0.8–4 MHz for HIFU therapy
• May be dual-function: treatment delivery + real-time imaging (combined in one probe)

• Transducer design (curvature, aperture, focal length)
• "On" and "off" beam time (duty cycle)
• Power delivered (in watts)
• Tissue acoustic properties

B. Ablation Zone Dimensions

C. Imaging & Monitoring Systems

1. Ultrasound Guidance (Most Common)

• The imaging transducer is mounted alongside or within the treatment probe — enabling real-time simultaneous treatment + imaging
• Hyperechoic (bright) changes on gray-scale ultrasound = microbubble/steam formation from heated tissue — confirms effective treatment
• Portable, inexpensive, widely accessible
• Limitation: Bubbles cause imaging artifacts that can obscure visualization; poor image quality in difficult cases

2. MRI Guidance (MRgFUS — Gold Standard for Precision)

• Uses MR thermometry to produce real-time temperature maps of the target zone and surrounding structures (urethra, sphincter, rectal wall)
• Provides superior anatomic resolution for accurate targeting
• More expensive, requires MR-compatible HIFU equipment and dedicated MRI suite
• Used for brain, uterine fibroids, bone, and emerging prostate applications

D. Safety Systems (Prostate Devices)

• Rectal cooling system: Circulating cool water within the endorectal probe protects the rectal wall from thermal injury
• Real-time rectal wall temperature monitoring
• Patient movement detection (automatic treatment pause if movement detected)
• Color-coded temperature display (Sonablate) for neurovascular bundle and rectal wall

---

7. Commercial HIFU Devices

1. Sonablate (SonaCare Inc., Indiana, USA)

• Mobile, minimally invasive
• Endorectal probe (transrectal approach)
• Treats prostates up to 40 mL
• Lesion size: 10–12 mm per sonication
• Robotic transducer for precise targeting throughout the gland
• Real-time color-coded temperature monitoring of treatment zone and adjacent critical structures
• mpMRI fusion imaging capability
• Operator can adjust power in real time based on tissue response
• Patient position: extended lithotomy

2. Ablatherm (EDAP TMS, Lyon, France)

• Semi-automated system
• Components: treatment module + control module + endorectal probe (dual transducer: treatment + imaging)
• Lesion size: 19–26 mm via predefined power protocols
• Real-time intraoperative imaging with adjustable energy delivery
• Rectal cooling + movement detection + rectal wall monitoring
• Power is preset (fixed protocols)
• Patient position: right lateral decubitus

3. MRgFUS Systems (e.g., ExAblate — InSightec)

• In-bore MRI guidance with real-time thermometry
• Superior targeting accuracy — spatial control within 1.3 mm
• Applications: uterine fibroids, bone metastases, brain (transcranial), prostate

4. TULSA (Transurethral Ultrasound Ablation)

• Miniaturized HIFU probe inserted transurethrally (not transrectally)
• In-bore MRI guidance
• Particularly suited for anterior prostate lesions inaccessible to transrectal HIFU
• Multicenter phase I trial: spatial control within 1.3 mm, 3.3% grade 3 complication rate, no grade 4/5 complications

— Campbell Walsh Wein Urology

5. LipoSonix™ (Aesthetic HIFU)

• Focal depth: 1.3 cm into subcutaneous fat
• Temperature up to 70°C — thermally destroys adipocytes
• FDA-cleared (2011) for non-invasive waist circumference reduction
• Single treatment reduces waist circumference by 2–3 cm

— Dermatology 2-Volume Set 5e

---

8. Step-by-Step Working / Procedure (Prostate Cancer Model)

Pre-Procedure Assessment

• Complete staging workup: PSA, multiparametric MRI (mpMRI), targeted + systematic biopsy
• Gleason score and tumor volume confirmation
• Zonal risk assessment (which zones harbor disease)
• Anticoagulant/antiplatelet medication management

Bowel Preparation

• Full bowel preparation the evening before, OR
• Enema administered 1 hour prior to surgery
• Purpose: optimize perirectal ultrasonographic imaging quality

Antimicrobial Prophylaxis

• Intravenous broad-spectrum antibiotics: metronidazole + cefuroxime + gentamicin (gram-negative and anaerobic coverage)
• Surgery postponed if active urinary tract infection or bacteriuria present
• Postoperative oral antibiotics: ciprofloxacin × 7 days

Anesthesia

• General or spinal anesthesia required (any patient movement impairs precision)
• Spinal: heavy sedation mandatory
• If prostate movement from breathing is detected → neuromuscular paralysis + ventilation
• ⚠️ Nitrous oxide is ABSOLUTELY CONTRAINDICATED — causes microbubble formation throughout the prostate, producing widespread artifacts that make safe energy delivery impossible

— Hinman's Atlas of Urologic Surgery; Miller's Anesthesia 10e

Intraoperative Steps

Post-Procedure Care

---

9. Ablation Zone Strategies (Prostate)

---

10. Indications

Prostate

• Localized prostate cancer (primary treatment):
  • Clinically significant disease: Gleason ≥ 3+4, volume > 0.2 mL
  • Focal, hemiablation, or whole-gland approach
  • Patients with comorbidities precluding surgery or radiation
• Salvage HIFU (after radiotherapy failure):
  • In an open-label trial (n=100): 81% of patients had negative biopsy at 12 months; 50/78 achieved PSA nadir ≤ 0.5 ng/mL
• BPH (benign prostatic hyperplasia) — symptomatic, refractory to medical therapy
• Emerging option for low-risk disease alongside cryotherapy (Schwartz's Principles of Surgery)

Other Organs

---

11. Contraindications / Limitations

---

12. Complications

Prostate HIFU Complications (Hinman's Atlas)

Salvage HIFU (Post-Radiation) — Higher Complication Rates

• 80 patients: Grade 2 toxicity
• 20 patients: Grade 3 toxicity
• Complications included: 5 rectal fistulas, 3 cases osteitis pubis, 3 cases recalcitrant hematuria requiring intervention

— Campbell Walsh Wein Urology

Aesthetic HIFU (LipoSonix™)

• Post-procedural pain (moderate to severe in some)
• Numbness, edema, ecchymoses

Breast HIFU (Systematic Review, 167 patients)

• Pain: 40.1%
• Edema: 16.8%
• Skin burn: 4.2%
• Pectoralis major injury: 3.6%

— Current Surgical Therapy 14e

---

13. Comparison with Other Ablative Modalities

— Current Surgical Therapy 14e

---

14. Advantages of HIFU

---

15. Erectile Function Outcomes (Prostate HIFU)

"Preservation of function with whole-gland high-intensity focused ultrasound (HIFU) is more common but may vary with the aggressiveness and oncologic efficacy of the procedure." — Campbell Walsh Wein Urology

• Focal/hemiablation HIFU: 60–78% recovery of erectile function
• Whole-gland HIFU: less favorable, but better than whole-gland cryoablation
• Re-treatment carries increased rates of erectile dysfunction and stricture

---

16. Oncologic Outcomes (Prostate)

Primary HIFU (Focal/Hemiablation)

• French hemiablation trial (n=111): Largest published series
• Infield positive biopsy rate: 15.5–34.6% (all cancer); 8.2–11.5% (clinically significant)
• Outfield positive biopsy: 7.7–36.7% (all cancer); up to 2% (clinically significant)
• Recurrence-free rate: 90% at 5 years, 38% at 10 years (early series, pre-MRI era)

Salvage HIFU (Post-Radiation)

• 81% negative biopsy at 12 months
• 64% (50/78) achieved PSA nadir ≤ 0.5 ng/mL with negative biopsy

---

17. Emerging Innovations

---

18. Summary Reference Table

---